Editorial Calendar (Related)
Editorial Guidelines (Related) SubscribeTo GEN (Related) To E-Alerts (Related) To RSS (Related) Advertise
2007 Media Kit (Related)
2007 Planning Calendar (Related) Contact Us (Related) About GEN (Related)
Breaking News
Patent Expiries Threaten $22bn of CNS Drug Sales, According to URCH Report Jun 6 2007, 5:13 AM EST
Business Wire
Just three of the 13 patented drugs that dominated the global
market for central nervous System (CNS) treatments in 2005 will be
free from generic competition in 2010, concludes a new report on the
CNS pharmaceutical market.
In 2005 there were 13 CNS drugs with sales of more than $1bn a
year - known as blockbusters - by the end of 2010, sales of all but
three of these therapies will be struggling against generic rivals,
says "CNS Market Trends 2007 to 2010 - Key market forecasts and growth
opportunities", from URCH Publishing.
In total, drugs accounting for 39.8% of total CNS sales in 2005
will lose patent protection by the end of 2010, followed by drugs
accounting for a further 19.5% of 2005 sales losing patent protection
by the end of 2015. Hardest hit by patent expiries over the next four
years are the CNS portfolios of Johnson & Johnson and GlaxoSmithKline,
who will each face generic competition for three of their leading CNS
drugs.
The 125 page report finds that the products hardest hit by generic
competition will be Pfizer's anti-depressant Zoloft and Wyeth's
serotonin-norepinephrine reuptake inhibitor Effexor. Selective
serotonin reuptake inhibitor Zoloft, generated global sales of US$3.3
billion in 2005, while Effexor, generated sales of US$3.5 billion.
However, generic competition following patent expiries in June 2006
for Zoloft and June 2008 for Effexor will erode sales of US$2.8
billion and US$2.3 billion respectively by 2010.
"As a result of significant generic competition the global
anti-depressants market is set to decline between 2005 and 2010,"
commented the report's author Steve Seget. "However, with the patent
estates for lead drugs, Zyprexa and Risperdal protecting against
generic competition beyond 2010, the anti-psychotics drug class is set
to overtake the anti-depressants drug class and become the leading
contributor to global CNS sales in 2010, he added.
"CNS Market Trends 2007 to 2010 - Key market forecasts and growth
opportunities" is available from URCH Publishing. Find more details at
http://www.urchpublishing.com/publications/therapeutic
/cns_market_trends_2010.html
(Due to its length, this URL may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)
About URCH Publishing Ltd (www.urchpublishing.com)
URCH Publishing Ltd is an independent business information
publisher dedicated to delivering quality information products to the
global pharmaceuticals industry.
No comments:
Post a Comment